首页> 美国卫生研究院文献>Neuro-Oncology >GENE-08. SECONDARY GLIOBLASTOMA IDH-WILDTYPE ARISING IN DIFFUSE ASTROCYTOMA IDH-MUTANT: A CASE REPORT
【2h】

GENE-08. SECONDARY GLIOBLASTOMA IDH-WILDTYPE ARISING IN DIFFUSE ASTROCYTOMA IDH-MUTANT: A CASE REPORT

机译:基因-08。二级胶质母细胞瘤衍射星形细胞瘤IDH突变体产生的IDH-野生素:案例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Primary glioblastoma develops de novo without clinical or histological evidence of a low-grade precursor lesion, while secondary glioblastoma develops from a low-grade glioma. The same IDH mutation is observed in almost secondary glioblastomas that occurs in low-grade gliomas with IDH mutation. Present report is an extraordinary case of secondary glioblastoma, IDH-wildtype arising in diffuse astrocytoma, IDH-mutant. A 31-year-old female presented with seizure 3 months ago, who had a history of operation for diffuse astrocytoma, IDH-mutant on the left frontal lobe 6 years ago. Magnetic resonance imaging test revealed new infiltrative lesions (6.5cm) in left frontal lobe and corpus callosum, in addition to the non-enhancing mass (3.4cm). New infiltrative lesion suspected anaplastic change and the patient underwent tumorectomy. Microscopically, non-enhancing lesion showed high cellularity, moderate nuclear atypia and brisk mitosis. Microvascular proliferation and necrosis were absent that can be diagnosis as anaplastic astrocytoma. However, new infiltrative lesion showed microvascular proliferation and necrosis that acceptable for diagnosis as glioblastoma. IDH-1 immunohistochemistry (IHC) was positive in anaplastic astrocytoma but negative in glioblastoma. In addition, we assessed NGS based on the SNUBH Brain v1.0 (Macrogen, Seoul, South Korea) panel. Similar to IHC result, IDH-1 (p.Arg132His) mutation was found in anaplastic astrocytoma but not in glioblastoma. Interestingly, ATRX (p.Gln1670Ter) and TP53 (p.His193Arg) mutations were found in both lesions. Additionally, PTEN (p.His296Pro) mutation was identified in glioblastoma component only. Until now, it is well-known hypothesis that the IDH mutation initiated in glial progenitor cell and the other genetic mutations occur sequentially in pathogenesis of secondary glioblastoma. Notably, this is the first case report that other genetic alterations can be initiated before IDH mutation contrary to previous hypothesis. In our case, mutation of ATRX and TP53 might be initiated, and PTEN and IDH-1 mutations were sequentially occurred in glioblastoma and anaplastic astrocytoma, respectively.
机译:原发性胶质母细胞瘤在没有低级前体病变的临床或组织学证据的情况下发育de novo,而二级胶质母细胞瘤从低级胶质瘤发育。在具有IDH突变的低级胶质瘤中发生的几乎副胶质细胞瘤中观察到相同的IDH突变。目前的报告是缩小星形细胞瘤,IDH突变体产生的次级胶质母细胞瘤的非凡案例。 3个月前缉获的31岁女性,他们在6年前左侧叶片上的弥漫星形细胞瘤,IDH突变体有历史。磁共振成像试验在左前叶和胼uc,除了非增强质量(3.4cm)外,磁共振成像试验显示了左前叶和胼um。新的渗透病变可疑血栓性变化和患者接受肿瘤切除术。显微镜,非增强病变显示出高细胞性,中度核原型和轻盈丝分裂。不存在微血管增殖和坏死,这可能是诊断作为轴突转换星形细胞瘤。然而,新的渗透病变显示微血管增殖和坏死,可用于诊断为胶质母细胞瘤。 IDH-1免疫组织化学(IHC)在气囊纤维细胞瘤中阳性,但在胶质母细胞瘤中是阴性的。此外,我们根据Snubh脑V1.0(宏观原,首尔,韩国)小组评估了NGS。类似于IHC结果,在包塑星形细胞瘤中发现IDH-1(P.ARG132HIS)突变,但不存在于胶质母细胞瘤中。有趣的是,在两个病变中发现ATRX(P.GLN1670Ter)和TP53(P.HIS193ARG)突变。另外,仅在胶质母细胞瘤组分中鉴定PTEN(P.HIS296PRO)突变。到目前为止,它是众所周知的假设,即在胶质祖细胞和其他基因突变中发起的IDH突变在次级胶质母细胞瘤的发病机制中依次发生。值得注意的是,这是第一种情况报告,即在与先前假设相反的IDH突变之前可以启动其他遗传改变。在我们的情况下,可以引发ATRX和TP53的突变,并且分别在胶质母细胞瘤和包层的星形细胞瘤中依次发生PTEN和IDH-1突变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号